Navigation Links
Comparison of venlafaxine and SSRIs in the treatment of depression
Date:2/21/2008

Philadelphia, PA, February 21, 2008 There are numerous antidepressant medications currently on the market, but sadly, many patients still experience the debilitating symptoms of depression even with treatment. A new study published in the February 15th issue of Biological Psychiatry set out to compare two popular classes of antidepressants, the newer serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine (Effexor), and the older selective serotonin reuptake inhibitors (SSRIs), like fluoxetine (Prozac) and citalopram (Celexa), to determine if one provides an overall greater benefit.

To do so, the authors performed a meta-analysis, by pooling the results of 34 double-blind randomized controlled trials that compared a single SNRI, venlafaxine, to other SSRIs. Dr. Charles Nemeroff, senior author on the paper, reports their findings: Venlafaxine was superior to SSRIs in efficacy overall, and moreover, statistically superior to fluoxetine but not to paroxetine, sertraline or citalopram. Venlafaxine had a higher dropout rate due to adverse events. These findings indicated a 5.9% advantage in remission rates for venlafaxine. The authors also report that the typical doctor would need to treat 17 patients to have a single patient benefit from being treated with venlafaxine rather than an SSRI.

Acknowledging the seemingly small advantage, John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments that this article highlights an advance that may have more importance for public health than for individual doctors and patients. He explains this reasoning:

If the average doctor was actively treating 200 symptomatic depressed patients and switched all of them to venlafaxine from SSRI, only 12 patients would be predicted to benefit from the switch. This signal of benefit might be very hard for that doctor to detect. But imagine that the entire population of depressed patients in the United States, estimated to be 7.1% of the population or over 21 million people, received a treatment that was 5.9% more effective, then it is conceivable that more than 1 million people would respond to venlafaxine who would not have responded to an SSRI. This may be an example of where optimal use of existing medications may improve public health even when it might not make much difference for individual doctors and patients.

Thus, in the typical clinical practice this difference constitutes a barely detectable benefit, but this difference could be meaningful across the large population of depressed patients in the United States.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
5. Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
6. Venlafaxine extended-release effective for patients with major depression
7. New treatment effective in counteracting cocaine-induced symptoms
8. New treatment boosts muscle function in myasthenia gravis
9. Broad-based group of physicians calls for improvement in stroke treatment
10. Cranberry Could Juice Up Ovarian Cancer Treatment
11. Non-medicinal treatment touted for pre-schoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... For over 20 years Sealy Baby ... for their babies. We take tremendous pride in using some of nature’s best materials ... classic, natural, and innovative crib mattresses and crib bedding for ...
(Date:7/28/2017)... ... July 28, 2017 , ... ... financial planning assistance to families and business owners in and around the greater ... held in honor of the Make-A-Wish Foundation. , The Make-A-Wish Foundation is an ...
(Date:7/28/2017)... , ... July 28, 2017 , ... ... Center for Shamanic Healing and Spiritual Awakening, is proud to announce the ... 2017. , Those interested in learning more about the mystical world of ...
(Date:7/27/2017)... ... ... Georgia Urology , the largest urology practice in the Southeastern United States, ... patients in the Braselton and Gainesville offices. The Braselton office is located at 7316 ... Wednesdays, and Fridays. The Gainesville office (675 White Sulphur Road, Suite 180, Gainesville), located ...
(Date:7/27/2017)... ... July 27, 2017 , ... Trusted dentist, speaker and ... sleep apnea in Wayne, NJ to receive custom treatment at his practice ... apnea with the use of custom-crafted oral appliances. Highly-trained in using the latest ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
(Date:7/25/2017)... July 25, 2017  Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited ... 25, 2017 at the Bonaventure Resort & Spa in Weston, Florida ... ... President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, ...
(Date:7/21/2017)... Md. and RESEARCH TRIANGLE PARK, ... Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before the market opens on Thursday, July 27, ... will host a teleconference on Thursday, July 27, 2017, ... by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A ...
Breaking Medicine Technology: